Nestlé Health Science has signed an exclusive agreement outside of the United States and Canada to support the potential future commercialisation of Seres Therapeutics ‘ novel ‘microbiome therapeutics’.
The aim is to treat Inflammatory Bowel Disease (IBD) and Clostridium difficile (C.diff), an intestinal infection caused by the C.diff bacteria that can be life-threatening in some cases.
Nestlé Health Science will invest USD 120 million upfront to support Seres’ ‘Ecobiotics’, a new class of biological drugs based upon microbial organisms. These target the microbiome – the 100 trillion microorganisms that live in the body.
Scientific has noted that research increasingly links an unhealthy or unbalanced microbiome to a range of health conditions, including IBD and C.diff.
Seres Therapeutics designs Ecobiotic® drugs using their proprietary microbiome therapeutics platform. This technology gives them insights into the microbiome associated with health and disease states, allowing them to create effective therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyze the establishment of healthy ones. Ecobiotic® drugs are designed to rapidly and safely treat serious diseases by positively reshaping the microbiome.
click on the graphic above to be directed to the Seres Therapeutics website.
To access full article click on the link below:
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.